Physician Views Benchmarking: Psoriasis

The market for therapies approved to treat moderate-to-severe psoriasis is currently one of the most competitive with the pharmaceutical industry.

Which of the leading psoriasis brands is deemed the most effective by prescribers, and which the least effective? Which has the most admired safety profile and which is considered the least safe by dermatologists? Which brand will benefit from the biggest increase in use over the next two to three years?

Our latest Physician Views snap-poll is being fielded to US and EU3 (France, Germany and the UK) based dermatologists to find out. To be notified when the results become available click here.

_______

Q. Which product approved for the treatment of moderate-to-severe psoriasis is the most effective?

Humira (adalimumab)

Enbrel (etanercept)

Remicade (infliximab)

Stelara (ustekinumab)

Cosentyx (secukinumab)

Taltz (ixekizumab)

Siliq (brodalumab)

Otezla (apremilast)

Ilumya/Illumetri (tildrakizumab)

Skyrizi (risankizumab)

Tremfya (guselkumab)

_______

Q. Which product approved for the treatment of moderate-to-severe psoriasis is the least effective?

Humira (adalimumab)

Enbrel (etanercept)

Remicade (infliximab)

Stelara (ustekinumab)

Cosentyx (secukinumab)

Taltz (ixekizumab)

Siliq (brodalumab)

Otezla (apremilast)

Ilumya/Illumetri (tildrakizumab)

Skyrizi (risankizumab)

Tremfya (guselkumab)

_______

Q. Which product approved for the treatment of moderate-to-severe psoriasis is the safest?

Humira (adalimumab)

Enbrel (etanercept)

Remicade (infliximab)

Stelara (ustekinumab)

Cosentyx (secukinumab)

Taltz (ixekizumab)

Siliq (brodalumab)

Otezla (apremilast)

Ilumya/Illumetri (tildrakizumab)

Skyrizi (risankizumab)

Tremfya (guselkumab)

_______

Q. Which product approved for the treatment of moderate-to-severe psoriasis is the least safe?

Humira (adalimumab)

Enbrel (etanercept)

Remicade (infliximab)

Stelara (ustekinumab)

Cosentyx (secukinumab)

Taltz (ixekizumab)

Siliq (brodalumab)

Otezla (apremilast)

Ilumya/Illumetri (tildrakizumab)

Skyrizi (risankizumab)

Tremfya (guselkumab)

_______

Which product approved for the treatment of moderate-to-severe psoriasis do you expect to increase your use of the most over the next 2/3 years?

Humira (adalimumab)

Enbrel (etanercept)

Remicade (infliximab)

Stelara (ustekinumab)

Cosentyx (secukinumab)

Taltz (ixekizumab)

Siliq (brodalumab)

Otezla (apremilast)

Ilumya/Illumetri (tildrakizumab)

Skyrizi (risankizumab)

Tremfya (guselkumab)

_______

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.